Novavax Inc. (NVAX)
Here's Why Novavax (NVAX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
Novavax Stock Soars on FDA Approval for COVID Vaccine
Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine.
Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.
Novavax shares surge 26% after FDA grants conditional approval for Covid vaccine
Novavax, Inc. (NASDAQ:NVAX) shares jumped 26% in premarket trading on Monday after the U.S. Food and Drug Administration granted full approval for its COVID-19 vaccine, though with narrower eligibility than expected.
FDA approves Novavax COVID vaccine with new conditions
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.
Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head, R&D Conference Call Participants Alec Stranahan - Bank of America Alec Stranahan Joining Day 2 of the 2025 Bank of America Healthcare Conference. My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Tom Shrader - BTIG Eric Joseph - JPMorgan Chris LoBianco - TD Securities Operator Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call.
